EU/3/17/1900

About

On 23 August 2017, orphan designation (EU/3/17/1900) was granted by the European Commission to Apogenix AG, Germany, for asunercept for the treatment of myelodysplastic syndromes.

Key facts

Active substance
Asunercept
Medicine name
-
Disease / condition
Treatment of myelodysplastic syndromes
Date of first decision
23/08/2017
Outcome
Positive
EU designation number
EU/3/17/1900

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Apogenix AG
Im Neuenheimer Feld 584
69120 Heidelberg
Germany
Tel. + 49 6221 58608 0
E-mail:contact@apogenix.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating